The long-term benefits of interferon-based therapy on preventing cirrhosis at non-cirrhotic stage in chronic Hepatitis C patients are not fully clarified.
Dr Lin and colleagues from Taiwan evaluated the effectiveness of interferon-based therapy regarding cirrhosis prevention in non-cirrhotic chronic Hepatitis C patients.
|15-year incidence of cirrhosis was 10% with treatment|
|Alimentary Pharmacology & Therapeutics|
The research team evaluated a total of 1386 biopsy-proven, non-cirrhotic chronic Hepatitis C patients.
The team reported that 892 patients received interferon-based therapy, and 494 untreated were enrolled.
The researchers noted that 56 patients were untreated and 51 were treated.
The team reported that 24 patients were sustained virologic responders, and 27 were non-responders.
Patients developed cirrhosis during a mean follow-up period of 5 years.
The annual incidences of cirrhosis in untreated and treated groups were 2% and 1%, respectively.
The team found that the annual incidence of cirrhosis in non-responders was 2%, and less than 1% in sustained responders.
The research team found that the 15-year cumulative incidence of cirrhosis was 10% in treated and 40% in untreated patients.
The team observed that the 15-year cumulative incidence of cirrhosis was significantly lower in sustained responders compared with non-responders and untreated patients.
The difference was not significant between non-responders and untreated controls.
The researchers showed with additional analysis that sustained virologic response was an independent negative factor for cirrhosis development.
In addition, the team noted that younger age was an independent negative factor for cirrhosis development.
Dr Lin's team concluded, “A sustained virologic response secondary to interferon-based therapy could reduce cirrhosis development in chronic Hepatitis C patients.”